Androgen Receptor Expression in Bladder Cancer: Prognostic Implications

Abstract

This retrospective cohort study evaluated androgen receptor (AR) expression in patients with urothelial bladder carcinoma diagnosed between 2016 and 2021. Immunohistochemical analysis was performed to assess the correlation between AR expression and prognosis (recurrence-free, progression-free, and overall survival). Although AR has been proposed as a potential therapeutic target, its prognostic value remains unclear. In this study, AR expression did not show significant associations with recurrence, progression, or survival outcomes. These findings suggest that AR may have limited value as a prognostic biomarker in bladder cancer, highlighting the need for further investigation into its clinical relevance.